1.20% -0.145

Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1118)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	11.96	3.81B	3.02B	127.93M	225.64M	0.2213
TAK Takeda Pharmaceutical Co Adr	17.82	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.66	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.05	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.84	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.19	23.35B	3.13B	1.27B	1.12B	26.39

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Overweight
2025-06-06	Eingeleitet	Goldman	Buy
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Fed Meeting: Does Amneal Pharmaceuticals Inc stock have upside surprise potential2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn

Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5%Here's What Happened - MarketBeat

Amneal Pharmaceuticals Inc (AMRX) Shares Gap Down to $12.73 on M - GuruFocus

Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance

What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders - simplywall.st

Amneal Pharmaceuticals Conference: “Amneal 2.0” Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift - MarketBeat

Amneal (AMRX) Stock Analysis 2026: Strong Gains vs. Future Growth ConcernsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Shorts Report: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdForecast Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Finviz

AMRX: Biosimilars and specialty launches fuel growth, with profitability and global expansion accelerating - TradingView

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Trade Report: Will Amneal Pharmaceuticals Inc benefit from current market trends2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn

Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Quantbot Technologies LP - MarketBeat

Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and Mail

Amneal to Participate in Upcoming Investor Conference - National Today

Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants - Stock Titan

Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs - Stock Titan

Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs - Stock Titan

Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs - Stock Titan

Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan

Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan

AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews

Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat

Truist raises Amneal Pharmaceuticals stock price target on margin focus By Investing.com - Investing.com Canada

Truist raises Amneal Pharmaceuticals stock price target on margin focus - Investing.com

Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating - marketscreener.com

Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat

Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - Sahm

Earnings Miss: Can Amneal Pharmaceuticals Inc be the next market leaderQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance

Envestnet Asset Management Inc. Takes $1.61 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript - Insider Monkey

Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative - Sahm

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release - simplywall.st

Earnings call transcript: Amneal Pharmaceuticals beats expectations in Q4 2025 - Investing.com Australia

Why Amneal (AMRX) Stock Is Trading Lower Today - Yahoo Finance

Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance - MarketBeat

Amneal Pharmaceuticals (NASDAQ: AMRX) grows biosimilars, Parkinson’s and injectables - Stock Titan

Amneal (AMRX) Q4 2025 Earnings Call Transcript - The Globe and Mail

Amneal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat

Amneal Q4 2025 slides: specialty surge drives 11% revenue growth - Investing.com

Amneal Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-02-27 - Seeking Alpha

Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million - Benzinga

Amneal Posts Strong Q4 Results and Raises 2026 Outlook - TipRanks

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026 - marketscreener.com

Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations - Finviz

Amneal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX